GHK-Cu vs Cortexin

GHK-Cu and Cortexin occupy distinct niches in peptide research. GHK-Cu, a naturally occurring tripeptide-copper complex, has been extensively studied for wound healing, collagen synthesis, and skin regeneration, with a robust safety profile from decades of cosmetic and clinical use. Cortexin, a complex mixture of low-molecular-weight polypeptides derived from porcine and bovine cerebral cortex, is registered as a pharmaceutical in Russia and CIS countries for neurological conditions such as ischemic stroke and cognitive impairment. While GHK-Cu targets peripheral tissue repair and aging, Cortexin focuses on neuroprotection and brain recovery. Their mechanisms, evidence bases, and regulatory statuses differ markedly, making selection dependent on specific research goals.

GHK-Cu (glycyl-L-histidyl-L-lysine) is a naturally occurring copper-binding tripeptide discovered by Dr. Loren Pickart in 1973. Plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60, suggesting an age-related physiological role. Its mechanism involves copper-dependent activation of matrix metalloproteinases and upregulation of collagen, elastin, and glycosaminoglycan synthesis, alongside modulation of over 4,000 genes related to tissue remodeling and antioxidant defense. Evidence spans decades: preclinical models demonstrate accelerated wound healing and reduced scar formation, while clinical studies show improved skin firmness and elasticity. The molecular weight is ~340 g/mol (as copper complex), with formula C14H24N6O4Cu. Key research claims include promotion of dermal regeneration, reduction of fine lines, and enhancement of wound repair. The evidence base is broad, with multiple peer-reviewed studies supporting its efficacy in topical and injectable forms.

Cortexin is a complex neuropeptide preparation containing a mixture of low-molecular-weight polypeptides (up to 10 kDa), amino acids, vitamins, and trace minerals derived from cattle and pig cerebral cortex. Unlike single-sequence peptides, it is a multi-component extract with pleiotropic effects. Registered as a pharmaceutical in Russia and CIS countries since 1999, it is indicated for neurological conditions including ischemic stroke, traumatic brain injury (TBI), and cognitive decline. Mechanistically, research demonstrates caspase-8 inhibition (anti-apoptotic), upregulation of brain-derived neurotrophic factor (BDNF), and antioxidant defense in models of cerebrovascular insufficiency. Evidence is drawn from clinical trials and observational studies in post-Soviet literature, but it lacks FDA or EMA approval, limiting Western acceptance. Key claims include neuroprotection in stroke, reduction of neuronal apoptosis, and cognitive support. The evidence strength is moderate, with a focus on multi-target neuroprotection rather than single-pathway specificity.

GHK-Cu and Cortexin target fundamentally different research domains with minimal overlap. GHK-Cu is predominantly investigated in skin health, anti-aging, and wound healing, leveraging its collagen-stimulating and antioxidant properties. Cortexin is exclusively studied in neuroprotection, stroke recovery, and cognitive support, with no established role in peripheral tissue repair. Researchers should note that while both have antioxidant effects, GHK-Cu’s antioxidant activity is copper-dependent and localized to extracellular matrix, whereas Cortexin’s is brain-specific. The shared theme of tissue repair is superficial; GHK-Cu addresses dermal and connective tissue, while Cortexin targets neuronal survival and synaptic plasticity. Selection should be driven by the tissue of interest and the desired mechanistic pathway.

GHK-Cu has an excellent safety profile from decades of cosmetic and clinical use (PMID: 29986520). Topical forms are well-tolerated, with mild skin irritation rare and limited to sensitive skin. Injectable forms may cause mild injection site reactions, lightheadedness, nausea, or flu-like symptoms; rotating injection sites reduces local irritation. No serious adverse events have been linked to GHK-Cu in controlled studies. Cortexin has a substantial clinical safety record through pharmaceutical use in Russia and CIS since 1999. The most common adverse effect is injection site reactions (pain, redness, swelling) from intramuscular administration. Rare allergic or hypersensitivity reactions have been reported, consistent with its animal-derived protein composition. Researchers should consider the risk of immunogenicity with Cortexin due to its complex, non-human origin, which is absent for the endogenous GHK-Cu peptide.